Grade My Investments

Haemonetics Corporation (HAE) Stock Grade

HAE · Healthcare

B
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$2.5B
P/E Ratio
26.2
Revenue Growth (YoY)
-2.0%
Net Margin
7.3%
Return on Equity
12.2%
Dividend Yield
None

About Haemonetics Corporation's fundamentals

Haemonetics Corporation, a $2.5 billion medical instruments company, is trading at a P/E ratio of 26.2 while experiencing a contraction in revenue with year-over-year growth of -2.0%. The company maintains a net profit margin of 7.3% and generates a return on equity of 12.2%, indicating modest profitability relative to shareholder capital. The company does not pay a dividend, suggesting it may be retaining earnings for reinvestment or debt management purposes.

Track HAE free — no credit card required. Live grade + monthly AI report →